Cortechs.ai | Neuroimaging biomarkers for AD

Neuroimaging biomarkers for AD

Structural Functional And Molecular Neuroimaging Biomarkers For Alzheimer’s Disease

Magnetic resonance spectroscopy (MRS) has long showed promise for detection of regional chemical changes associated with neurodegeneration, infl ammation, or gliosis, and so it has been a technique of interest for detecting such changes in AD. It provides information about relative concentrations of key chemicals, such as N acetylaspartate, creatinine, and myoinositol, and there is strong evidence that the regional concentration of these chemicals varies with the neurodegeneration seen in AD. (2013).

[button]Download[/button]

More Resources

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.

02/11/2026

NeuroQuant Normative Database: Advancing Age‑ and Sex‑Specific Brain Volumetry

Learn how the latest updates to the NeuroQuant normative database white paper strengthen age- and sex-specific brain volumetry and enhance clinical confidence.
Scroll to Top